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ABSTRACT Tuberculosis (TB) is one of the leading causes of death due to a sin-
gle infectious agent. The development of a TB vaccine that induces durable and
effective immunity to Mycobacterium tuberculosis (Mtb) infection is urgently
needed. Early and superior Mtb control can be induced in M. bovis Bacillus
Calmette-Guérin (BCG)-vaccinated hosts when the innate immune response is tar-
geted to generate effective vaccine-induced immunity. In the present study, we
show that innate activation of DCs is critical for mucosal localization of clonally
activated vaccine-induced CD41 T cells in the lung and superior early Mtb con-
trol. In addition, our study reveals that Th1/Th17 cytokine axis play an important
role in superior vaccine-induced immunity. Our studies also show that activation
of the nuclear factor kappa-light-chain enhancer of activated B cell (NF-kb) path-
way in lung epithelial cells is critical for the mucosal localization of activated vac-
cine-induced CD41 T cells for rapid Mtb control. Thus, our study provides novel
insights into the immune mechanisms that can overcome TB vaccine bottlenecks
and provide early rapid Mtb control.
IMPORTANCE Tuberculosis is a leading cause of death due to single infectious
agent accounting 1.4 million deaths each year. The only licensed vaccine, BCG, is
not effective due to variable efficacy. In our study, we determined the early
immune events necessary for achieving complete protection in a BCG-vaccinated
host. Our study reveals that innate activation of DCs can mediate superior and
early Mtb control in BCG-vaccinated mice through lung epithelial cell signaling
and localization of clonal activated, Mtb antigen-specific, cytokine-producing
CD41 T cells within the lung parenchyma and airways. Thus, our study provides
novel insights into the immune mechanisms that can overcome TB vaccine bot-
tlenecks and provide early rapid Mtb control.
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M ycobacterium tuberculosis (Mtb) is a leading cause of death worldwide by a singleinfectious agent, and it infects approximately one-fourth of the world’s population
(1). Currently, Mycobacterium bovis Bacillus Calmette-Guerin (BCG) is the only licensed
vaccine against tuberculosis (TB). However, the variable efficacy of BCG, along with the
emergence of drug-resistant Mtb strains and comorbidity associated with human immu-
nodeficiency virus infection, has further confounded the eradication of TB as a public
health problem. Recently, the M72/AS01E vaccine has been reported to provide about
50% efficacy in Mtb-infected adults against pulmonary TB disease (2). In addition, use of
BCG vaccination either mucosally or intravenously (i.v.) in rhesus macaques substantially
limited Mtb infection (3–5). However, despite these breakthrough findings in the TB vac-
cine field, we do not fully understand the mechanistic basis behind the early immune
events within the lungs that mediates protection in vaccinated hosts.
T cells are required to control Mtb in vivo since mice lacking CD41 T cells are unable
to control Mtb infection (6). Mtb infection is known to delay initiation of the adaptive T
cell immune response, resulting in early uncontrolled Mtb growth (7–9). Moreover, dur-
ing Mtb infection, the colocalization of immune cells, including CD41 T cells and mac-
rophages within the lung parenchyma rather than in the lung vasculature, is critical for
early Mtb control (10, 11). However, the exact mechanisms that mediate the recruit-
ment of CD41 T cells in vaccinated hosts to mediate Mtb control is unclear. In the pres-
ent study, using a mouse model of early superior Mtb control in BCG-vaccinated hosts,
we have delineated the early protective mechanisms that mediate vaccine-induced
Mtb control. We demonstrate that the localization of clonally expanded Mtb-specific
cytokine-producing CD41 T cell populations which preferentially localize in the lung
parenchyma and airways is critical for early Mtb control. In addition, early signaling
events in lung epithelial cells are critical to facilitate the interaction between activated
Mtb-specific CD41 T cells and macrophages, within the parenchyma and airways, for
rapid Mtb control in this model. Thus, our study provides novel immunological insights
into the early mechanism of vaccine-induced protective immunity against TB, allowing
for potential targeting these pathways to improve TB vaccine efficacy for future use.
RESULTS
Innate activation of DCs amplifies clonal vaccine-induced CD4+ T cell responses
inMtb-infected BCG-vaccinated mice. Delayed activation and accumulation of Mtb-spe-
cific vaccine-induced T cells in the lung is a critical bottleneck for vaccine protection
againstMtb infection (8, 9). Innate activation by transfer of exogenously zymosan-activated
Mtb antigen 85B (Ag85B)-pulsed DCs (Z-DCs) into BCG-vaccinated Mtb-infected hosts
resulted in early CD41 T cell recruitment, enhanced gamma interferon (IFN-g) and interleu-
kin-17 (IL-17) production, and complete early control of Mtb replication in mice (8). Using
this published model of early and superior vaccine-induced Mtb control, we probed the
exact immune mechanism(s) of protection in vaccinated hosts. The peak of the CD41 T cell
response in unvaccinated Mtb-infected mice is 20days postinfection (dpi), while the peak
of the vaccine response is 15dpi after Mtb infection (12). We also showed that in Vac1Z-
DC group, the vaccine responses are accelerated at 8 and 15dpi (8). Therefore, we picked
the peak time point as the appropriate measurement of effective T cell responses between
the conditions in order to assess their full expression of antimycobacterial function. As a
first step, lung cells were isolated at the peak of the immune response, respectively, from
Mtb-infected unvaccinated C57BL/6 mice at 20dpi (Unvac), Mtb-infected BCG-vaccinated
C57BL/6 mice at 15dpi (Vac), andMtb-infected BCG-vaccinated C57BL/6 mice that received
Z-DC transfer (given intratracheally [i.t.] at 21 and 14dpi) at 8 and 15dpi (Vac1Z-DC)
(Fig. 1A) and subjected to single cell RNA sequencing (scRNA-Seq) to define the immune
cell populations driving enhanced vaccine-induced immunity.
In CD31 cells, unsupervised clustering yielded four clusters of CD41 cells, namely,
naive CD41 cells (Ccr71 Sell1), two clusters of effector CD41 cells (Ccr7– Sell– CD441 or
Ifng1), and T regulatory cells (Foxp31); three clusters of CD81 cells—naive CD81 cells
(Ccr71 Sell1), cytotoxic CD81 cells (Gzmb1 Prf11), and a mix of CD81 and Tgd cells; and
more enriched Tgd cluster (Trgv21) (Fig. 1B and C; see also Fig. S1A and Table S1 in the
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FIG 1 Activation of DCs amplifies rapid CD41 T cell responses in BCG-vaccinated Mtb-infected mice. C57BL/6 (B6)
mice were either left unvaccinated (UnVac) or vaccinated with BCG (Vac), rested for 4weeks, and infected with Mtb
(Continued on next page)
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supplemental material). Notably, clusters of naive CD41 T cells dominated in both Mtb-
infected unvaccinated and BCG-vaccinated mice and decreased in Mtb-infected BCG-
vaccinated mice that received Z-DC transfer (40% versus 20% of T cells). In contrast,
effector CD4_1 cluster dominated the T cell population in Mtb-infected BCG-vaccinated
mice that received Z-DC transfer (harvested at either 8 or 15 dpi), while being almost
absent in Mtb-infected BCG-vaccinated or unvaccinated mice (35 to 55% versus ,10%
of total T cells, Fig. 1D; see also Fig. S1B). Effector CD4_1 exhibited the signature of
lung T resident memory (Trm) cells, including Cxcr3, Cxcr6, Itgae, Cd44, Cd69, and
Cd101 (13) (Fig. 1E; see also Fig. S1C). We have used the publicly available surface re-
ceptor markers of Trm cells in lungs of humans as a broad lung T cell tissue-resident
signature (13, 14). Gene set enrichment analysis (GSEA) shows an enrichment of genes,
upregulated in lung Trm (GSE94964), in our comparison between CD4_1 and CD4_2/
Naive CD4 clusters. Incidentally, we also identified a T-cell receptor (TCR) for each cell
and first compared the clonotype expansion with the Gini coefficient (a coefficient of 0
means that each T cell clonotype has only one T cell, while coefficient of 1 means that
all T cells have identical clonotype). CD41 cells from Mtb-infected BCG-vaccinated mice
that received Z-DC transfer had a Gini coefficient twice higher than Mtb-infected
unvaccinated or BCG-vaccinated mice, suggesting that Mtb-infected BCG-vaccinated
mice that received Z-DC transfer have more expanded clonotypes compared to CD41
T cells in Mtb-infected unvaccinated or BCG-vaccinated mice (Fig. 1F).
We also identified potential motif-based groups of CD41 T cells recognizing the same
epitopes derived from antigens among the TCRs using the TCRdist tool. We focused on
the three most well-defined motifs with conserved amino acids, coming from TCR clusters
of size 108, 19, and 49 TCRs (Fig. 1G and H; see also Fig. S1D and Table S2). Since TCRdist
operates on unique TCR sequences without taking into account clonotype expansion, we
enumerated the number of CD41 T cells expressing any of these TCR motifs, and we found
that motif 1 was exclusively associated with Mtb-infected BCG-vaccinated mice that
received Z-DC transfer, where it was present in 10 to 25% of all CD41 T cells (Fig. 1I, left
panel; see also Fig. S1E), while other motifs were much less expanded. Motif 1 is character-
ized by TRAV3-3–TRAJ27/37/52–TRBV16 pairing, and it features submotifs in both CDR3a
and CDR3b . Conserved amino acids come from V and J gene parts rather than from inser-
tion of random nucleotides. Furthermore, we found that majority of cells with motif 1
belonged to effector CD4_1 cluster (Fig. 1I, right panel), accounting for .20% of cells
inside the cluster. We next analyzed transcriptional differences among the CD41 T cells
between different groups. Therefore, we isolated the CD41 T cells (at the time of peak
CD41 T cell responses) from Mtb-infected unvaccinated C57BL/6 mice at 20dpi, Mtb-
infected vaccinated C57BL/6 mice at 15dpi, and Mtb-infected vaccinated C57BL/6 mice
that received Z-DC transfer at 8dpi (Fig. 1J; see also Fig. S2A). Among the top 25 differently
expressed genes in the Mtb-infected BCG-vaccinated mice that received Z-DC transfer,
there was a marked upregulation of genes associated with T cell migration, including Ccr8
(15), Itgae (Cd103) (16), Aqp3 (17), and Rbpj associated with cell-cell communications (18).
Surprisingly, gene expression profile of CD41 T cells from Mtb-infected unvaccinated or
BCG-vaccinated mice were comparable (Fig. 1J; see also Fig. S2A and B). The important
FIG 1 Legend (Continued)
HN878. (A) Some BCG-vaccinated mice received Z-DCs (Vac1Z-DC) at the time of Mtb infection. Lungs were harvested at
different dpi, and single cell suspensions were subjected to scRNA-Seq. (B) UMAP results with lung isolated CD31 cells,
combined plot shown from unvaccinated (20 dpi) (n=2), vaccinated (15 dpi) (n= 2), and Vac1Z-DC (8 and 15dpi) (n= 1
and n= 2, respectively) conditions are presented here. (C) UMAPs with marker genes used to assign identity to clusters
of T cells are shown. CD41 cluster abundances as percentages of total CD31 cells across four conditions are shown. Error
bars indicate means 6 the standard deviations (SD) for two replicates from each condition. (D) Vac1Z-DCs at 8 dpi had
only one replicate. (E) Mean expressions of genes, upregulated (left panel) or downregulated (right panel) in lung T
resident memory (Trm) cells on UMAP for all conditions. (F) Gini coefficient for CD41 repertoires across all samples. (G)
TCRdist tree result for 7,677 unique CD41 TCRs. (H) Amino acid composition of CDR3a and CDR3b for motif 1 depicted
as sequence logo. (I) Proportions of CD41 cells, matching motif 1 across all samples (left panel) and across CD41 clusters
(right panel). (J) The gene expression profile of total CD41 T cells isolated from Mtb-infected unvaccinated (20 dpi), Mtb-
infected BCG-vaccinated (15 dpi), and Mtb-infected BCG-vaccinated C57BL/6 mice that receive Z-DC transfer (8 dpi) was
determined by RNA sequencing. Z-scores were calculated from the FPKM values across all of the samples, individually
for each gene. n= 5 biological replicates for gene expression profile analysis.
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enriched pathways associated with T cells receptor signaling and T cell function were
observed in the Mtb-infected BCG-vaccinated mice that received Z-DC transfer compared
to the CD41 T cells isolated from BCG-vaccinated mice (see Fig. S2C). Therefore, our data
suggest that CD41 T cells that confer early Mtb control in Mtb-infected BCG-vaccinated
mice that received Z-DC transfer express functionally distinct T cell transcriptional profiles
associated with migration.
Early activation and mucosal localization of CD4+ T cells mediates improved
Mtb control in a BCG-vaccinated host. We next determined the functional ability of
the vaccine-induced CD41 T cells to promote macrophage killing of Mtb. We isolated
highly pure lung CD41 T cells from either Mtb-infected BCG-vaccinated C57BL/6 mice
(at 15 dpi) or Mtb-infected BCG-vaccinated C57BL/6 mice that received Z-DC transfer
(at 8 dpi) and cocultured isolated CD41 T cells with Mtb-infected macrophages in vitro
to assess Mtb killing. Interestingly, both CD41 T cells from Mtb-infected BCG-vaccinated
mice and Mtb-infected BCG-vaccinated mice that received Z-DC transfer effectively
mediated comparable Mtb killing (Fig. 2A). In addition, while IFN-g production was sim-
ilar in supernatants from cocultures of both groups that received CD41 T cells (Fig. 2B),
higher levels of IL-17 were detected in cocultures that received CD41 T cells from Mtb-
infected BCG-vaccinated mice that received Z-DC transfer compared to cocultures that
received Mtb-infected BCG-vaccinated CD41 T cells (Fig. 2C). Since we did not find any
functional differences in Mtb killing within macrophages between the two groups, we
hypothesized that the clonally expanded CD41 T effector population was mediating
improved protection, possibly due to other mechanisms rather than just direct activa-
tion of macrophages. Thus, we next isolated highly pure lung CD41 T cells from
Mtb-infected vaccinated mice that received Z-DC transfer (at 8 dpi) and adoptively
transferred the CD41 T cells into the BCG-vaccinated C57BL/6 mice following Mtb
infection, whereas control mice were BCG-vaccinated and Mtb infected and did not
receive T cells. The rationale was to test whether adoptive transfer improved Mtb con-
trol compared to just BCG vaccination. Adoptive transfer of purified CD41 T cells into
Mtb-infected BCG-vaccinated mice resulted in improved Mtb control, compared to
phosphate-buffered saline (PBS)-treated Mtb-infected BCG-vaccinated mice (Fig. 2D),
and this coincided with improved B cell follicle formation associated with immune con-
trol of Mtb (19), without impacting overall lung inflammation (Fig. 2E and F). This
improved Mtb control coincided with dampened production of proinflammatory cyto-
kines in the lungs of Mtb-infected BCG-vaccinated mice that received CD41 T cells,
including IL-12, tumor necrosis factor alpha (TNF-a), IL-10, IL-1b , and IL-6, and the che-
mokines KC, MIP-1b , RANTES, and MIP-2 (Fig. 2G and H) corroborating with the unal-
tered overall lung inflammatory landscape. Together, these results suggest that
vaccine-induced CD41 T cell drive protection in Mtb-infected BCG-vaccinated hosts
likely by their ability to migrate and localize into specific lung compartments.
Therefore, we next studied the kinetics associated with the CD41 T cell activation, as
well as localization of CD41 T cells, in the lungs of Mtb-infected BCG-vaccinated mice
and Mtb-infected BCG-vaccinated mice that received Z-DC transfer. Remarkable CD41
T cell activation (CD44hi) was observed as early as 3 dpi (gating strategy in Fig. S2D) in
Mtb-infected BCG-vaccinated mice that received Z-DC transfer, and this correlated with
significant and rapid accumulation of Mtb Ag85B tetramer-specific (TET1) CD41 T cells
within the lungs of Mtb-infected BCG-vaccinated mice that received Z-DC transfer com-
pared to Mtb-infected BCG-vaccinated mice (Fig. 3A; see also Fig. S3A). These robust
and early responses were maintained, with 8 dpi being the peak of the response. We
observed nearly 400-fold higher CD41 CD44hi TET1 T cells in Mtb-infected BCG-vacci-
nated mice that received Z-DC transfer compared to Mtb-infected BCG-vaccinated
mice. In contrast, the expansion and accumulation of CD41 CD44hi TET1 T cells in Mtb-
infected BCG-vaccinated mice was delayed until 20 dpi (Fig. 3A).
Immune cell recruitment in airways and parenchyma correlated with increased pro-
tection compared to localization in lung vasculature during Mtb infection (11, 20). To
identify the localization of activated T cells to specific lung compartments, we tracked
vasculature localization (CD45.2-BV6051), airway localization (CD45.2-V5001), and
Epithelial Signaling Mediates VaccineMtb Control ®















































FIG 2 Adoptive transfer of vaccine-induced CD41 T cells mediates improved Mtb control in a BCG-vaccinated host. CD41 T cells
were isolated from Mtb-infected BCG-vaccinated C57BL/6 mice and Mtb-infected BCG-vaccinated C57BL/6 mice that received
(Continued on next page)
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parenchyma localization (BV605– V500–) of immune cells in the lung (10, 11, 21) by
administering anti-CD45.2-BV605 intravascularly or anti-CD45.2-V500 intratracheally
just prior to sacrifice. We found that CD41 CD44hi (see Fig. S3B), CD41 CD44hi TET1
T cells (Fig. 3B) localized to the lung parenchyma of Mtb-infected BCG-vaccinated mice
that received Z-DC transfer at very early time points (3 to 15 dpi), with progressive
accumulation of CD41 CD44hi cells and CD41 CD44hi TET1 T cells into the airways over
time. Coincident with the delayed accumulation of CD41 CD44hi TET1 T cells in
Mtb-infected BCG-vaccinated mice, the majority of the CD41 CD44hi TET1 T cells local-
ized mainly in vasculature and parenchyma, with some cells localizing within the air-
ways (Fig. 3B, inset). These data together suggest that activation of the innate immune
pathways to target vaccine-induced T cell responses can initiate rapid expansion of
CD41 CD44hi TET1 T cells with specific localization in the lung parenchyma and air-
ways, contributing to early and rapid Mtb control.
CXCR3 is a well-described chemokine receptor expressed by circulating T cells. As infec-
tion progressed, the accumulation of CD41 CD44hi TET1 CXCR31 T cells increased into the
lung parenchyma and airways in Mtb-infected BCG-vaccinated mice that received Z-DC
transfer (Fig. 3C). However, reduced accumulation of CD41 CD44hi TET1 CXCR31 T cells in
the lung parenchyma and airways in Mtb-infected BCG-vaccinated mice was observed
(Fig. 3C, inset). The CD41 CD44hi TET1 CXCR31 cells which expanded at day 15 postinfec-
tion exhibited a ratio of parenchyma: vasculature associated T cells of 16.69 6 10.54 in
Vac1Z-DC mice compared to BCG-vaccinated mice (3.7946 6.572, P = 0.0489 [as deter-
mined by Student t test between Vac1Z-DC and BCG-vaccinated Mtb-infected mice]). IFN-
g and IL-17 are important effector cytokines that contribute to protective immune
responses against Mtb infection (3, 22, 23). Although the majority of the CD41 CD44hi
TET1 T cells were IL-171 cytokine producing, a population of IFN-g1 cytokine-producing
and IFN-g1/IL-171 double cytokine-producing CD41 CD44hi TET1 T cells was also found in
the lungs of Mtb-infected vaccinated mice that received Z-DC transfer, and they accumu-
lated as early as 5 dpi with peak responses at 8 dpi (Fig. 3D). Importantly, the cytokine-pro-
ducing CD41 CD44hi TET1 T cells predominantly localized to the lung parenchyma and air-
ways. Moreover, in Mtb-infected BCG-vaccinated mice that received Z-DC transfer, the
frequency of IL-171 cytokine-producing CD41 CD44hi TET1 T cells showed an early and
sustained increase compared to IFN-g1 and IFN-g1/IL-171 cytokine-producing CD41
CD44hi TET1 T cells. Indeed, consistent with delayed accumulation of CD41 CD44hi TET1 T
cells in Mtb-infected BCG-vaccinated lungs, the numbers of IFN-g1 and IL-171 single or
dual cytokine-producing CD41 CD44hi TET1 T cells were delayed and 10-fold lower in Mtb-
infected BCG-vaccinated mice, and these cells preferentially localized in the vasculature
(Fig. 3E). To fully characterize the role of cytokine signaling in Z-DC-mediated protection in
the BCG-vaccinated Mtb-infected mice, we transferred Z-DCs in BCG-vaccinated IL-17/IL-22
double knockout (Il-17/Il-222/2) mice with or without IFN-g neutralization to evaluate the
specific contribution of Th1 and/or Th17 responses. The absence of IL-17/IL-22 signaling
together led to significantly higher bacterial burdens (Fig. 3F) compared to wild-type BCG-
vaccinated C57BL/6 mice which also received the Z-DC transfer. These results suggest an
important role for IL-17/IL-22 signaling, specifically under conditions of the superior pro-
tection enabled by Z-DC transfer in BCG-vaccinated mice. In addition, we observed
reduced expression of major histocompatibility complex class II (MHC-II) expression on al-
veolar macrophages (AMs) (Fig. 3G; see also the gating strategy in Fig. S3C) within the
FIG 2 Legend (Continued)
Z-DC transfer and cocultured with Mtb-infected BMDMs (1:1 ratio) for 6 days. (A) Intracellular Mtb CFU was determined by
plating cell lysates. (B and C) IFN-g and IL-17 levels were measured in cell supernatants by ELISA. n= 3 to 5 biological
replicates. C57BL/6 mice were vaccinated with BCG, rested for 4weeks, and infected with Mtb HN878. CD41 T cells were
isolated from Mtb-infected BCG-vaccinated mice that received Z-DC transfer (at 8 dpi) and adoptively transferred to Mtb-
infected BCG-vaccinated mice. (D) Lungs were harvested at 30 dpi, and the lung bacterial burden was determined by plating.
(E) Lung inflammation was calculated in the hematoxylin/eosin-stained FFPE lung sections. (F) B cell lymphoid follicle formation
was determined on the FFPE lung sections by B220 (red) immunofluorescence staining. n= 3 to 9 mice per group. (G and H)
The levels of cytokines (G) and chemokines (H) in lung homogenates were quantified by multiplex. n= 5 biological replicates.
Data represent means 6 the SD. ND, not detected. **, P # 0.01; ***, P # 0.001 (determined either by one-way ANOVA [A to C]
or by Student t test [actual P values are shown] [D to H]).
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FIG 3 Rapid and early CD41 T cell activation and localization within lung parenchyma and airway is driven by CCR8 engagement. C57BL/6 mice were
vaccinated, Mtb infected, and received Z-DC transfer as described in Materials and Methods. At the time of harvest, the mice received anti-CD45.2-v500 (i.t.)
(Continued on next page)
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lungs of BCG-vaccinated Il-17/Il-222/2 mice receiving the Z-DC transfer. Moreover, blocking
IFN-g in BCG-vaccinated Il-17/Il-222/2 mice that also received Z-DC transfer abrogates Mtb
control, with significant reduction in expression of MHC-II expression on AMs and reduced
accumulation of CD41 CD44hi TET1 T cells compared to the wild-type BCG-vaccinated
C57BL/6 mice receiving Z-DC transfer (Fig. 3G and H). Therefore, our study points toward a
synergistic role played by the Th1-Th17 axis in mediating better protection in BCG-vacci-
nated Mtb-infected mice receiving Z-DCs. These results suggest that the protection medi-
ated in the Mtb-infected BCG-vaccinated mice that received Z-DC transfer is associated
with an early activation, expansion, and localization of cytokine-producing CD41 T cells
within the parenchyma and airways whereMtb-infected macrophages are harbored.
Both scRNA-Seq and bulk gene signature analysis of CD41 T cells demonstrated ele-
vated expression of genes associated with migration, such as Itgae, or the genes
expressed by tissue-resident T cells such as the chemokine receptor, Ccr8 (Fig. 1B and
I). Expression of CD103 and CCR8 on CD41 CD44hi TET1 T cells peaked on 8 and 15 dpi,
respectively, which corresponded to the enhanced recruitment of CD41 CD44hi TET1 T
cells into lungs and the early control of Mtb replication in BCG-vaccinated mice that
received Z-DC transfer (Fig. 3I and J [and insets]). In addition, Mtb-infected Cd103-defi-
cient BCG-vaccinated mice that received Z-DC transfer exhibited similar protective
capacities compared to Mtb-infected wild-type mice that also received Z-DC transfer
(see Fig. S3D), suggesting that CD103 expression did not induce additional protective
mechanisms in BCG-vaccinated mice that received Z-DC transfer. In contrast, Ccr8-defi-
cient Mtb-infected BCG-vaccinated mice receiving Z-DC transfer did not control Mtb
replication to a level similar to that observed in wild-type Mtb-infected BCG-vaccinated
mice that received Z-DC transfer (Fig. 3K). This decreased vaccine-induced control in
Ccr8-deficient Mtb-infected BCG-vaccinated mice receiving Z-DC transfer coincided
with reduced accumulation of CD41 CD44hi TET1 T cells within the lungs of Ccr8-defi-
cient mice (Fig. 3L). These results suggest CD103-independent but CCR8-dependent
mechanisms underlying Z-DC-mediated vaccine-induced Mtb control. However, it is
also possible that CCR8, along with CD103, synergistically regulates the CD41 T cell
localization and activation to impact Mtb replication in vivo, and this requires further
experimentation.
Lung epithelial signaling is critical for early immune cell activation and mucosal
localization in Mtb-infected vaccinated mice. Our data demonstrate that mucosal
localization of CD41 T cells within the parenchyma and airways is effective at inducing
complete early Mtb control in vaccinated hosts. Our recent studies showed that AMs
upon activation migrate from the airways into the parenchyma to form granulomas
and mediate effective Mtb control (10). Thus, we next addressed whether localization
of CD41 T cells in the parenchyma and airways resulted in more effective and early
activation of AMs. We observed that AMs readily accumulated in the lung airways and
parenchyma of Mtb-infected BCG-vaccinated mice that received Z-DC transfer (Fig. 4A;
see also the gating strategy in Fig. S3C) with increasing accumulation and rapid early
upregulation of MHC-II expression as an indicator of activation (Fig. 4B). In contrast,
AM localization within the airways in Mtb-infected BCG-vaccinated mouse lungs was
delayed with fewer AMs that accumulated within the parenchyma and delayed timing
FIG 3 Legend (Continued)
and anti-CD45.2-BV605 (i.v.) antibodies as described in Materials and Methods. (A) Lungs were harvested and subjected to flow cytometry to measure the
number of CD41 CD44hi TET1 T cells. (B, C, D, E, I, and J) The distributions of CD41 CD44hi TET1 (B), CD41 CD44hi TET1 CXCR31 (C), CD41 CD44hi TET1
cytokine1 (D and E), CD41 CD44hi TET1 CD1031 (I), and CD41 CD44hi TET1 CCR81 (J) T cells in groups of BCG-vaccinated mice were measured in lung
airways (red bar), parenchyma (blue bar), and vasculature (green bar) regions by flow cytometry. n= 4 to 5 mice per group. B6 and IL-17/IL-222/2 mice
were vaccinated with BCG, rested for 4weeks, and infected with Mtb HN878 and received Z-DCs. (F) One group of BCG-vaccinated Mtb-infected IL-17/IL-
222/2 mice received IFN-g neutralizing ab. Mice were harvested at 20 dpi, and the lung bacterial burden was determined by plating. (G and H) The MHC-II
MFI (mean fluorescence intensity) on AMs (G) and the numbers of CD41 CD44hi TET1 T cells (H) were assessed by flow cytometry on total lung single cell
suspensions. n= 4 to 5 mice per group. (K) B6 and Ccr82/2 mice were vaccinated with BCG, rested for 4weeks, and infected with Mtb HN878. Some BCG-
vaccinated mice received Z-DCs. Mice were harvested at 20 dpi, and the lung bacterial burden was determined by plating. Frequency of CD41 CD44hi TET1
T cells (L) were assessed by flow cytometry on total lung single cell suspensions. n= 4 to 8 mice per group. Data represent means 6 the SD.*, P # 0.05; **,
P # 0.01; ***, P # 0.001; ****, P # 0.0001 (determined either by two-way ANOVA [A to E, I, and J], one-way ANOVA [F to H], or Student t test [actual P
values are shown] [K and L]).
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FIG 4 NF-kb signaling in lung epithelial cells mediates early CD41 T cell activation and mucosal localization. C57BL/6 mice were vaccinated, Mtb infected,
and received Z-DCs as described in Materials and Methods. To track the myeloid cells, mice were given anti-CD45.2-v500 and anti-CD45.2-BV605 antibodies
through i.t. and i.v. routes, respectively, prior to harvest. (A to D) Lungs were harvested at different dpi, and total numbers of AMs (A), the MHC-II MFI on
AMs (B), RMs (C), and the MHC-II MFI on RMs (D) in airways (red bar), parenchyma (blue bar), and vasculature (green bar) location were assessed by flow
cytometry. n= 4 to 5 mice per group. In a separate experiment, Ikkfl/fl and Ikkfl/fl Sftpcre mice were vaccinated with BCG, infected, and received Z-DCs as
described in Materials and Methods. To track the immune cells, mice were given anti-CD45.2-v500 and anti-CD45.2-BV605 antibodies through i.t. and i.v.
routes, respectively, prior to harvest. (E) Lungs were harvested at 20 dpi, and the lung bacterial burden was determined by plating. (F) B cell lymphoid
follicles were determined by CD3 (red) and B220 (green) staining on FFPE lung sections by immunofluorescence staining. The total numbers of AMs (G),
(Continued on next page)
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of AM activation. In BCG-vaccinated mice, while there is no significant accumulation of
AMs in the parenchyma, there is a small but significant increase in the AM population
within the airways at 15 dpi compared to 8 dpi. In addition, we observed a marked
early recruitment and activation of recruited macrophages (RMs), mainly in the airways
and lung parenchyma of Mtb-infected BCG-vaccinated mice that received Z-DC trans-
fer. In contrast, in the Mtb-infected BCG-vaccinated mice, RMs localized mainly in the
vasculature and to a lesser extent in the parenchyma (Fig. 4C and D). Thus, collectively
our data suggest that early infiltration and localization of myeloid cells within specific
lung parenchyma are crucial factors for inducing superior vaccine-induced immunity.
Epithelial cells respond to IL-17 and IL-22 (24–26) and secrete various antimicrobial
peptides and several chemokines (27) that orchestrate recruitment of immune cells,
such as neutrophils, recruited monocytes, and natural Th17 cells (28, 29). Thus, we
hypothesized that activation of epithelial signaling will participate in production of
mediators involved in strategic immune cell localization and early control of Mtb infec-
tion. To further delineate mechanistic insight of the signaling pathways associated
with the superior vaccine-induced immunity in Mtb-infected BCG-vaccinated mice that
received Z-DC transfer, we used Ikkfl/fl Sftpcre mice that lack NF-kb signaling specifically
in lung type II epithelial cells and therefore do not upregulate the expression of neces-
sary inflammatory cytokines or chemokines (10, 30). The absence of functional lung
epithelial signaling in Mtb-infected BCG-vaccinated Ikkfl/fl Sftpcre mice that received
Z-DC transfer did not provide the superior and early vaccine-induced Mtb control com-
pared to the Mtb-infected BCG-vaccinated Ikkfl/fl littermate control mice that received
Z-DC transfer (Fig. 4E). These data suggest that functional epithelial signaling plays an
important role in inducing the superior protection specifically under conditions of
Z-DC transfer into BCG-vaccinated mice following Mtb infection. Moreover, we
observed reduced B cell follicle formation within the lungs of Mtb-infected BCG-vacci-
nated Ikkfl/flSftpcre mice that received Z-DC transfer compared to Mtb-infected BCG-vac-
cinated littermate control mice that received Z-DC transfer (Fig. 4F). To further
investigate the influence of functional epithelial signaling on immune mechanisms, we
studied the immune cell localization in Mtb-infected BCG-vaccinated Ikkfl/fl Sftpcre and
littermate control mice that received Z-DC transfer. As expected, we observed reduced
AM accumulation within the lung parenchyma in Mtb-infected BCG-vaccinated Ikkfl/
fl Sftpcre mice that received Z-DC transfer compared to Mtb-infected BCG-vaccinated lit-
termate controls mice that received Z-DC transfer (Fig. 4G). Although we did not see
any defects in the accumulation of RMs in Mtb-infected BCG-vaccinated Ikkfl/fl Sftpcre
mice that received Z-DC transfer (Fig. 4H), we observed defective activation of RMs in
Mtb-infected BCG-vaccinated Ikkfl/fl Sftpcre mice that received Z-DC transfer compared
to Mtb-infected BCG-vaccinated littermate control mice that received Z-DC transfer
(see Fig. S3E). Moreover, we found a significant reduction in the number of CD41
CD44hi and CD41 CD44hi TET1 T cells present in the lung parenchyma of Mtb-infected
BCG-vaccinated Ikkfl/fl Sftpcre mice that received Z-DC transfer compared to Mtb-infected
BCG-vaccinated littermate control mice that received Z-DC transfer (Fig. 4I; see also
Fig. S3F and G). Similarly, the number of CD41 CD44hi TET1 IL-171 cytokine-producing
T cells present in the lung parenchyma of Mtb-infected BCG-vaccinated Ikkfl/fl Sftpcre
mice that received Z-DC transfer was significantly reduced compared to Mtb-infected
BCG-vaccinated littermate control mice that received Z-DC transfer (Fig. 4J). The num-
ber of CD41 CD44hi TET1 IFN-g1 cytokine-producing CD41 T cells present in lung air-
ways and parenchyma of Mtb-infected BCG-vaccinated Ikkfl/fl Sftpcre mice that received
Z-DC transfer was lower compared to Mtb-infected BCG-vaccinated littermate control
mice that received Z-DC transfer, although the number was not statistically significant
(Fig. 4K). Thus, our data suggest that activation of lung epithelial signaling regulates
FIG 4 Legend (Continued)
RMs (H), and CD41 CD44hi TET1 (I) and CD41 CD44hi TET1 cytokine1 (J and K) T cells in the airways, parenchyma, and vasculature were determined by flow
cytometry (red = Ikkfl/fl, n= 4 to 9; blue = Ikkfl/fl Sftpcre, n= 4 to 8). Data represent means 6 the SD. *, P # 0.05; **, P # 0.01; ***, P # 0.001; ****, P # 0.0001
(determined either by two-way ANOVA [A to D, G to K] or by Student t test [actual P values are shown] [E and F]).
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the environmental signals that mediate localization and amplification of Th17/Th1
responses within the site of infection to mediate early superior control of Mtb infection
in the vaccinated host.
DISCUSSION
The development of a TB vaccine that induces durable and effective immunity to
Mtb infection is urgently needed. Previously, we have demonstrated that complete
and early Mtb control can be induced in BCG-vaccinated hosts when the innate
immune response is targeted to generate effective vaccine-induced immunity. In the
present study, we show that the mechanisms by which activation of innate immunity
results in superior Mtb control is through rapid and robust amplification of cytokine-
producing vaccine-induced T cell responses and localization within the airways and pa-
renchyma of BCG-vaccinated hosts. Our studies also show that activation of NF-kb
pathway in lung epithelial cells is an important early event that drives the localization
of vaccine-induced CD41 T cells within parenchyma and activation of myeloid cells,
thus promoting the formation of protective iBALT structures within the lung and con-
trol of Mtb replication. Therefore, our study provides novel insights into the immune
mechanisms that can overcome TB vaccine bottlenecks and provide early rapid Mtb
control.
Mtb is a successful pathogen due to its ability to evade host immune responses.
Studies have shown that after Mtb infection, a delay in the activation of antigen-spe-
cific CD41 T cell responses occurs, likely due to Mtb’s ability to directly inhibit MHC-II
transactivator expression, MHC-II expression, and antigen presentation (31). BCG vacci-
nation can generate systemic vaccine-induced T cell responses, but upon Mtb chal-
lenge, the accumulation of T cells to the lung, although accelerated compared to naive
hosts (day 15 compared to day 20 in naive hosts), is still not sufficiently early or durable
enough to provide complete protection against Mtb infection (8, 32). Therefore, as
shown in our previous work (8) and by others (33), targeting the innate pathway
through DC activation is one way to rapidly activate T cell responses to mediate early
and rapid control. Our new studies presented here demonstrate that the mechanisms
by which innate DC activation overcomes the roadblock is by rapid amplification of
early CD41 T cell responses by 5 days after Mtb challenge and localization within air-
way and parenchyma compartments in the lung. That these CD41 T cells are recruited
and localized within 5 days is by far the earliest recruitment of vaccine-induced T cells
responses to most vaccine strategies against TB. This early amplification is similar to
what is seen in even after 30 days following BCG i.v. vaccination in nonhuman primates
where the heightened and lung-localized Trm cells are considered to be a mechanism
through which complete control of Mtb infection is mediated (3). In the present study,
we show that adoptive transfer of peptide pulsed Z-DC into BCG-vaccinated mice pro-
vides superior Mtb control. We have previously shown that after BCG vaccination (34),
the accumulation of antigen-specific lung-resident cytokine-producing T cells in the
lung is not as robust as amplification of antigen-specific T cells in the spleen and lymph
nodes of vaccinated mice. Based on these data, we expect that adoptive transfer of
Z-DC results in activation of antigen-specific T cells in the lymph nodes and possibly
recruitment to the lung. However, we do not rule out the possibility of local prolifera-
tion of T cells following Z-DC transfer. Thus, our results, along with recent studies,
including i.v. (3) and mucosal (5) BCG use, suggest that overcoming the Mtb suppres-
sion-mediated of early immune responses is thus possible and that generating lung-
resident activated T cell pool should be a good strategy for improving vaccine-induced
immunity against TB.
During Mtb infection, Ag85B is predominantly secreted during the early phase of
infection and expression reduced by 3weeks postinfection, while ESAT-6 is expressed
and secreted by Mtb during chronic phases of infection (35). Since we are interested in
the early events postinfection, we designed our study to activate innate immune
responses to amplify BCG-vaccine induced Ag85B-specific CD41 T cell responses
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against Mtb infection. Indeed, our results show that early amplification of Ag85B-spe-
cific T cell responses resulted in complete control of Mtb infection. Since several vac-
cine formulations, including whole vaccines such as BCG and subunit vaccines such as
H56/IC31 (36) and H56/CAF01 (37), include Ag85B as an antigen, our results suggest
that targeting innate DC activation to rapidly amplify Ag85B-specific CD41 T cell
responses may further improve upon protection elicited by these vaccines in animal
models and should be robustly tested. Furthermore, our studies for the first time
demonstrate that in fact the transcriptional profiles that are induced in BCG vaccine-
induced CD41 T cell responses are comparable to CD41 T cells induced in unvacci-
nated Mtb-infected mice, suggesting that the quality of responses induced by BCG
vaccination is not very different from Mtb infection. This is in sharp contrast to the early
amplification of vaccine-induced CD41 T cells found in BCG-vaccinated hosts that
undergo innate DC activation where there was a marked upregulation of genes associ-
ated with T cell migration and cell-cell communications, especially the expression of
genes such as Cd103 and Ccr8 which likely allow localization of effector T cells into
lung compartment for optimal Mtb control. Thus, our results also provide novel
insights that both the timing of arrival of CD41 T cells and the quality (cytokine pro-
duction and upregulation of receptors and proteins enabling lung localization) of
CD41 T cells are important for optimal Mtb control compared to CD41 T cells induced
by BCG vaccination that are not fully protective.
For the first time as far as we are aware, our study was able to identify potential
motif-based groups of CD41 T cells recognizing the epitopes of same antigens among
the TCRs. Our results showed that a motif was exclusively associated with T cells in
Mtb-infected BCG-vaccinated mice that received Z-DC transfer, where it was present in
10 to 25% of all CD41 T cells. These results suggest that innate DC activation of T cells,
along with amplification of CD41 T cells, also allows for clonal expansion of activated
Trm cells. Previous studies have demonstrated that in mice vaccinated with Ag85B had
a skewed CDR3b length distribution with preferential use of TRBV16 and two CDR3bs
namely, CASSLEGDEQYF and CASSLEGDTQYF (32). Our studies have not only validated
the presence of the CDR3b motifs but also identified the motif on CDR3a that are
amplified in CD41 T cells from BCG-vaccinated mice that also received Ag85B-primed
Z-DCs. Our studies identified three CDR3a and three CDR3b motifs highly represented
in effector CD41 T cells from BCG-vaccinated mice that also received Ag85B-primed
Z-DCs. From the available literature (32), the predominant motif 1 appears to be spe-
cific for Mtb Ag85B. The presence of “LEG” motif in the TCR sequence specifically in
TCRb identifies the TCR specific for Ag85B. Carpenter et al. (32) showed the TCRb
repertoire of vaccine-elicited (Ag85B240–254) and Mtb-recalled Ag85b-specific CD41
T cells, as well as after primary infection.
Therefore, unlike the unvaccinated or BCG vaccine-induced TCR repertoire on CD41
T cells, the Z-DC-induced TCR repertoire demonstrated in this study represents novel
motifs which have potential to control Mtb infection. Thus, while bulk RNA-Seq studies
do not allow us due to the pooled nature of cells to understand the heterogeneity of
T cell responses, scRNA-Seq allows us to understand the heterogeneity of T cell
responses. For example, our results show that while the activated population of clo-
nally expanded CD41 T cells expressing Trm markers increases in a BCG-vaccinated
host receiving Z-DC transfer, this population is not different between BCG-vaccinated
and unvaccinated lungs. Instead, an IFN-g1 CD41 T cell population is increased in BCG-
vaccinated lungs compared to unvaccinated lungs. Therefore, our results highlight the
utility of using single cell TCR sequencing to probe the expansion and clonality of vac-
cine-responsive CD41 T cells and provide an in-depth understanding of T cell
responses generated following vaccination.
During Mtb infection, effective control of intracellular Mtb requires direct recogni-
tion of infected macrophages in the lung by CD41 effector T cells (38). Therefore, local-
ization of Trm CD41 T cells in the lung is an important event required for Mtb control.
CXCR3 expression on CD41 T cells (CXCR31) is considered a marker of lung recruited
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CD41 T cells and is important for the localization of CXCR31 Th1 cells to the lung pa-
renchyma (11). In contrast, a subset of CD41 Th1 cells that are highly differentiated
(Tbet1) and coexpressing KLRG1 are present in the lung vasculature and are not effi-
cient in controlling Mtb growth (11). Adoptive transfer of the less-differentiated
CXCR31 KLRG– CD41 purified parenchymal T cells provided protection upon Mtb chal-
lenge, whereas the CXCR31 KLRG11 T cells are not protective upon transfer. In human
studies, CXCR51 CCR51 T cells in the lungs and pleural fluid produced IFN-g (39–41). In
preclinical macaque model of latent and active TB, CXCR31 CCR61 coexpressing T cells
produced both IL-17 and IFN-g cytokines in bronchoalveolar lavage (BAL) fluid and
were associated with the protective responses in latent TB (42). Finally, in vaccine mod-
els of subunit vaccination, CXCR31 KLRG– T cells readily trafficked to the lung paren-
chyma and provided Mtb control (37). With the increased resolution provided by our
studies using a combination of i.t. and i.v. labeling, allow us to further discriminate
whether immune cells are localized within the airways or parenchyma or the vascular
compartments. Our studies using this new technique show that BCG vaccination indu-
ces a mixed population of CXCR31 T cells that is distributed equally between the
vasculature, the parenchyma, and the airway compartments. In sharp contrast, BCG-
vaccinated hosts that also receive Z-DC transfer show a remarkable enhancement of
CXCR31 T cells that localize within the airway and parenchyma compartments.
Our study shows that upon BCG vaccination, the primary lung localizing T cells are
IL-17-expressing cells that accumulate by day 15, with IFN-g-producing cells accumulat-
ing by day 21 after Mtb infection. In contrast, BCG-vaccinated mice that receive Z-DC
transfer recruit Th17 cells by 5 days mostly in the airways and parenchyma, followed
by IFN-g-producing or IFN-g/IL-17-coproducing cells accumulating largely in the air-
ways and parenchyma by day 8. Both IFN-g and IL-17 have varied roles in Mtb control
during vaccination. In the case of IFN-g, while recent data have shown that IFN-g (43)
and IFN-g produced by CD41 T cells (21) are considered redundant, IL-17 is necessary
for vaccine-induced control in many models of vaccination (12, 34, 44). More recent
work from our lab has also demonstrated a critical role for IL-22 in mediating Mtb con-
trol. Intriguingly in our model described here, our results show a combined role for IL-
17/IL-22 and IFN-g in conferring early vaccine-induced control of Mtb infection.
Therefore, it is likely that the mucosal delivery of activated DCs accelerated parenchy-
mal homing of antigen-specific CD41 T cell subsets to gain access to the Mtb-infected
cells in the granuloma and reduce Mtb replication through activation of signaling
involving both Th1/Th17 cytokine axis.
Upregulation of Itgae (Cd103) and Ccr8 genes in CD41 T cells isolated from BCG-vac-
cinated Mtb-infected mice that received Z-DC transfer suggest that these molecules
may regulate CD41 T cell migration and localization within the lung compartments.
CD103 is an integrin highly expressed in tissue-resident memory T cells (21) and associ-
ated with epithelial retention of T cells through binding to E-cadherin expressed by
epithelial cells (45). CD103-expressing T cells are present in the lung and BAL fluid but
absent in blood of Mtb-infected humans, suggesting that CD103-expressing cells are
present at the site of Mtb infection. CD103-expressing T cells are enriched at the lung
parenchyma and airways following mucosal vaccination with BCG or Bacillus subtilis
spore fusion protein 1 (Spore-FP1) and confer better protection against Mtb infection
compared to BCG parenteral vaccination (46, 47). Thus, retention of CD103-expressing
T cells at the lung interface is likely necessary for providing protection against infec-
tion. A deficiency of Cd103 (in mice) correlated with a reduced number of mucosal
intraepithelial T cells (48). Our results show that despite the increased expression of
CD103 on CD41 T cells isolated from BCG-vaccinated Mtb-infected mice that received
Z-DC transfer and localization within the airway and parenchyma, CD103-deficient
mice upon BCG vaccination and Z-DC transfer still provided similarly superior protec-
tion as BCG-vaccinated wild-type C57BL/6 mice that received Z-DC transfer. These
results suggest redundant features of integrin that may mask the effect of single defi-
ciency of this protein, and compensatory mechanisms are being induced to ensure
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control of Mtb replication in CD103-deficient vaccinated mice that receive Z-DC trans-
fer. Our studies also show for the first time that CCR8 expression is high on CD41 T
cells isolated from BCG-vaccinated mice receiving Z-DC transfer and expression is high-
est on airway localized Ag85b-specific CD41 T cells. CCR8 is commonly expressed by T
regulatory subsets or T helper type 2 cells for efficient migration of T cell population to
the site of inflammation (49). CCL1 was shown to be upregulated upon in vitro infec-
tion with Mtb and in patients with active tuberculosis versus latently infected controls
(50, 51). However, the functional role of CCR8-expressing CD41 T cells during Mtb
infection remains elusive. Our studies show a functional role for CCR8 expression in the
superior protection mediated by the Z-DC transfer in BCG-vaccinated mice, since the
absence of CCR8 expression abrogates Z-DC-mediated protection and accumulation of
Ag85B-specific T cells. Together, these results suggest that CD103 and CCR8 play a piv-
otal role in early CD41 T cell recruitment and localization in the airways and paren-
chyma to achieve effective control of Mtb.
In recent studies, we proposed a role for AMs to localize from airways into the lung
parenchyma as an effector mechanism of protection upon Mtb infection (10).
Consistent with this proposed role for AMs in early Mtb control, our new results here
demonstrate that during BCG vaccination AMs continue to be retained within the air-
ways, while in BCG-vaccinated hosts, which also received Z-DC transfer, AMs are acti-
vated rapidly (day 8) and migrate into the parenchyma compartment. In sharp con-
trast, the AMs in BCG-vaccinated mice take up to 20 days to undergo activation.
Similarly, recruited macrophages in BCG-vaccinated mice are mostly located within the
vasculature, while Z-DC transfer activates the RMs to migrate into the airway. These
responses appear to be mediated by signaling in epithelial cells as mice deficient in
NF-kb signaling in CCSP1 epithelial cells abrogate AM accumulation, downstream acti-
vation, and accumulation of IL-17-producing Ag85B-specific CD41 T cells in the lung.
Epithelial cells respond to several external stimuli, including IL-17 and IL-22, and acti-
vate NF-kb-dependent signaling pathways to produce chemokines and other chemo-
tactic factors required to favor other immune cell recruitment and transmigration into
inflamed tissues (29, 52). Based on the increased susceptibility of mice lacking NF-kb
signaling in epithelial cells compartment, we propose that epithelial cells play an im-
portant role in mediating transmigration and specific localization of immune cells
within lung parenchyma after being activated by IL-17 and/or IL-22. Lung epithelial
cells can produce chemokines such as CXCL9, -10, and -11 (53) and CXCL13 in the pres-
ence of various stimuli (19, 54). Our published data show that IL-17 and IL-22 cytokines
are inducers of chemokines following Mtb infection (8, 19, 25, 34, 44). In addition, our
published data suggest an important role of the CXCL13/CXCR5 in organizing the
iBALT structures which help in rapid containment of the disease (19). Moreover, IL-17
cytokine is also involved in the initial formation of the iBALT structures following Mtb
infection in mice (26). Therefore, our results show that innate activation of DCs results
in activation of epithelial signaling in the lung to amplify accumulation of CD41 T cells
that localize within the airways and parenchyma to induce Mtb killing of infected
macrophages.
In conclusion, using a model of early complete Mtb control in BCG-vaccinated hosts
we show that rapid and early clonal expansion of activated cytokine-producing CD41 T
cells in the lung airway and parenchyma compartment are critical for mediating com-
plete and early vaccine-induced protection in Mtb-infected mice. Importantly, these
protections are driven by early signaling events in the lung epithelial cells that provide
the signals required for localization of CD41 T cells within the parenchyma for activa-
tion of macrophages, the formation of iBALT structures, and subsequent Mtb killing.
Our studies support the emerging idea that Th1/Th17-like activated CD41 T cells are
associated with models of sterilizing protection in macaques (23) and in vaccine-
induced protection in a human TB vaccine M72/AS01E trial (55). Understanding the
early immune parameters that mediate effective and early Mtb control as
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demonstrated here will shed novel insights into the mechanisms by which vaccine-
induced CD41 T cells can be enhanced to mediate complete control of Mtb.
MATERIALS ANDMETHODS
Mice. C57BL/6 (B6), B6.129P2-Il10tm1Cgn/J (Il102/2), and B6.129S2(C)-Itgaetm1Cmp/J (Itgae2/2 or
Cd1032/2) mice were obtained from Jackson Laboratory (Bar Harbor, ME) and bred at Washington
University. Cryopreserved sperm from Ccr82/2 mice were generously donated by Gwendalyn Randolph
from Washington University, and the in vitro fertilization was performed in the Micro-Injection Core at
Washington University School of Medicine. Ikkfl/fl Sftpcre mice were kindly provided by M. Pasparakis
(University of Cologne). Il-222/2 (28) and Il-172/2 (56) single knockouts were crossed and bred at
Washington University to generate Il-17/Il222/2 mice. Mice were age and sex matched and used
between 6 and 8weeks of age. All mice were used and housed in accordance with the National
Institutes of Health guidelines for housing and care of laboratory animals. All the experiments in this
study were approved by the Washington University Institutional Animal Care and Use Committee under
protocol 20160129.
IFN-c in vivo neutralization. A total of 300mg/ml of anti-IFN-g blocking antibody (clone XMG1.2;
BioXcell) was administered intraperitoneally every other day starting at 8 dpi until the harvest at 20 dpi.
Bacterial infection and vaccination. M. bovis Bacille Calmette-Guerin (BCG Pasteur [source,
Trudeau Institute]) and Mtb W. Beijing strain, HN878 (BEI Resources) were grown to mid-log phase in
Proskauer Beck medium containing 0.05% Tween 80 and frozen in at –80°C. Mice were vaccinated with
1 106 CFU of BCG subcutaneously and 4weeks later infected with;100 CFU of Mtb HN878 via an aero-
sol route using a Glas-Col airborne infection system. At given time points following infection, lungs were
collected and homogenized, and the tissue homogenates were plated after serial dilutions on 7H11 agar
(BD Bioscience) to assess the bacterial burden (8).
In vitro culture of BMDCs and transfer. Bone marrow-derived dendritic cells (BMDCs) and bone
marrow-derived macrophages (BMDMs) were generated as previously described (8). Briefly, cells isolated
from the femur and tibia were cultured at 1 106 cells/ml in 10ml of complete DMEM (cDMEM) supple-
mented with 4% recombinant mouse granulocyte-macrophage colony-stimulating factor (GM-CSF;
Peprotech, Rocky Hill, NJ) at 37°C in 7.5% CO2. After 3 days, 10ml of cDMEM supplemented with 4%
mouse GM-CSF was added, and incubation continued until day 7. At day 7, nonadherent cells (BMDCs)
were collected, counted, plated at 2 106 cells/ml in cDMEM, and rested overnight at 37°C in 7.5% CO2;
BMDCs were then stimulated overnight with Ag85B (20mg/ml; New England Peptide) and Zymosan
(25mg/ml; Sigma) to induce maturation and activation. Mature pulsed BMDCs were collected and
washed, and 1 106 cells in 50ml of PBS were instilled intratracheally (i.t.) at 21 and 14 dpi. For all the
adoptive transfer of Z-DCs, Il102/2 BMDCs were used.
Generation of single-cell suspensions from tissues. Lung single-cell suspensions from vaccinated
or Mtb-infected mice were isolated as previously described (57). Briefly, mice were euthanized with CO2,
and lungs were perfused with heparin in saline. Lungs were minced and incubated in collagenase/
DNase for 30 min at 37°C. Lung tissue was pushed through a 70-mm nylon screen to obtain a single cell
suspension. Red blood cells were lysed, and the cells were resuspended in suitable media or buffer for
further use.
CD4+ T cell isolation for RNA sequencing and adoptive transfer. Single cell suspensions from
infected mice were obtained as described previously (8). CD41 T cells from differently treated mice were
isolated using CD41 microbeads according to the manufacturer’s instructions (Miltenyi Biotec). The pu-
rity of CD41 T cells was analyzed by flow cytometry after staining with anti-CD4 antibody and reported
to be .95%. For the RNA-Seq analysis, cells were collected in RLT buffer with b-mercaptoethanol and
processed according the manufacturer’s instructions (Qiagen). For T cell transfer, 2 106 CD41 T cells
were transferred via the i.t. route in PBS into each mouse as previously described.
RNA-Seq data analysis. Purified mouse lung CD41 T cells were snap-frozen in RLT buffer, and
DNase-treated total RNA was extracted using an RNeasy minikit (Qiagen). RNA-Seq libraries were gener-
ated using a Clontech SMART-Seq v4 Ultra Low Input RNA kit for sequencing and an Illumina Nextera XT
DNA Library preparation kit according to the manufacturer’s protocol. Raw sequencing reads were qual-
ity checked for potential sequencing issues and contaminants using FastQC. Adapter sequences, pri-
mers, Ns, and reads with quality score below 28 were trimmed using fastq-mcf of ea-utils and PRINSEQ.
Reads with a remaining length of,20 bp after trimming were discarded. Paired-end reads were mapped
to the mouse genome (mm10) using STAR in a strand-specific manner. The read coverage on forward
and reverse strands for genome browser visualization was computed using SAMtools, BEDtools, and
UCSC Genome Browser utilities. Pairwise differential expression was quantified using DESeq2 (version
1.24.0), with default settings and a 10-5 adjusted P value cutoff for significance, and DESeq2-normalized
read counts were used to calculate relative expression (FPKM) values. Heatmap figures were generated
in Microsoft Excel, using Z-scores calculated from the FPKM values across all of the samples, individually
for each gene. Principal component analysis (PCA) was performed according to default DESeq2 settings,
utilizing the top 500 most variable genes across all samples. Lists of significantly differentially expressed
genes were used to test for significant enrichment among KEGG pathways (58) using WebGestalt (59)
(default settings, adjusted P= 0.05 threshold for enrichment).
scRNA-Seq library generation and sequencing. Isolated total lung single cell suspensions were
enriched for live cells using dead cell depletion kit according to manufacturer’s instructions (Miltenyi
Biotec) and subjected to droplet-based massively parallel single-cell RNA sequencing using a Chromium
Single Cell 59 (v3) reagent kit according to the manufacturer’s instructions (10x Genomics). Briefly, cell
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suspensions were loaded at 1,000 cells/ml to capture 10,000 cells/lane. The 10x Chromium Controller
generated GEM droplets, where each cell was labeled with a specific barcode, and each transcript was la-
beled with a unique molecular identifier (UMI) during reverse transcription. The barcoded cDNA was iso-
lated and removed from the BSL-3 space for library generation. The cDNA underwent 11 cycles of ampli-
fication, followed by fragmentation, end repair, A-tailing, adapter ligation, and sample index PCR
according to the manufacturer’s instructions. Libraries were sequenced on a NovaSeq S4 (200 cycle) flow
cell, targeting 50,000 read pairs/cell.
scRNA-Seq analysis. Sample demultiplexing, barcode processing, and single-cell 59 counting was
performed using the Cell Ranger Single-Cell Software Suite (10x Genomics, version 3). The Cell Ranger
cell count was used to align samples to the reference mm10 genome and quantify and filter reads with
a quality score below 30. For TCR, the Seurat package (60) in R was used for subsequent analysis. Cells
with mitochondrial content greater than 10% were removed. Filtered data were normalized using a scal-
ing factor of 10,000 nUMI was regressed with a negative binomial model, and data were log trans-
formed. The highly variable genes were selected using the FindVariableFeatures. PCA was performed
using the top 3,000 variable genes. Clustering was performed using the FindClusters function. UMAP
was used to project cells into two dimensions using 15 first principal components. For T cell reclustering,
we chose clusters that were identified as T cells (Cd3d1). For these 24,758 cells, we performed normaliza-
tion, found variable genes, and performed PCA, UMAP, and clustering as described above. All visualiza-
tion was done using the ggplot2 R package (61), and heatmaps were prepared using the Phantasus
website (https://artyomovlab.wustl.edu/phantasus/).
Public bulk RNA-Seq reanalysis. We reanalyzed the publicly available GSE94964 data set. With
Phantasus, we filtered low expressed genes and did log2(exp11) and quantile normalization. Further, to
get the T resident memory signature for CD41 T cells, we compared CD41 CD691 samples from the lung
with CD41 CD69– samples from the lung and blood with limma. We have taken 500 upregulated genes.
To compare with effector CD4_1 cluster from our data, we ran the FindMarkers function for CD4_1
cluster versus CD4_2 and CD4 naive cells with the MAST algorithm, a logFC threshold of 0.15, and a
“min.pct“ parameter of 0.2. We used the resulting ranked gene list and 500 upregulated genes from the
GSE94964 data set as a signature to run GSEA with the fgsea package.
Single cell paired TCRa/TCRb repertoire analysis. Sample demultiplexing and barcode processing
was performed using the Cell Ranger Single-Cell Software Suite (10x Genomics). Cell Ranger VDJ v3 was
used to align reads to the reference genome (vdj_GRCm38_alts_ensembl) and assemble TCRs. For
downstream analysis, only TCRs with one productive rearrangement for TCRa chain and one productive
rearrangement for TCRb chain were selected. Frequencies of clonotypes were calculated based on num-
ber of cells that pass quality control, as described above, and share both TCRa and TCRb nucleotide
sequences. The Gini coefficient was computed with the gini function from the TCR R package. To infer
motifs, TCRdist tool was used (62) on all TCRs that satisfied two criteria: that they belonged to CD4 T
cells and that they had exactly one TCRb and one TCRa chain with CDR3 sequence that passed Cell
Ranger quality control. TCRdist was run with default settings for a “mouse” organism. We chose three
motifs that were most abundant among unique clonotypes, without accounting for clonotype expan-
sion. To characterize the motif and match it to TCRs, we chose the most conservative stretches amino
acids to represent each motif: “NTGKL” in TCRa and “SLE” in TCRb for motif 1, “NNNNAP” in TCRa and “E
[TR]L” for motif 2, and “NAYKV” in TCRa and “SLE” in TCRb for motif 3. All clonotypes that contained
these sequences were classified as motif-bearing clonotypes. To calculate frequencies of cells for motifs,
we calculated how many cells are having motif-bearing TCR clonotype. Further, motif-bearing TCRs
were used to visualize motifs by first performing multiple sequence alignment with the msa R package
(ClustalW algorithm) and after representing the motifs with the ggseqlogo R package.
Intratracheal and intravascular staining.Mice were anesthetized with isoflurane before the i.t. and
i.v. staining. For i.t. staining, 0.7mg/mouse of anti-CD45.2-v500 ab (clone 104; BD Biosciences) in 50ml of
PBS was instilled through an i.t. route 15 min before the harvest. For the i.v. staining, 2.5mg/mouse of
anti-CD45.2-BV605 ab (clone 104; BD) in 100ml of PBS were injected into the retro-orbital sinus 3 min
before the harvest using a 26-gauge needle and a tuberculin syringe (10).
Flow cytometry staining. The following antibodies were obtained from TonBo Biosciences: MHC-II
(clone M5/114.15.2), IFN-g (clone XMG1.2), and CD4 (clone RM4-5). Antibodies purchased from
eBioscience (San Diego, CA) were as follows: CD103 (clone 2E7), CD44 (clone IM7), and CXCR3 (clone
CXCR3-173). CD11b (clone M1/70), CD11c (clone HL3), Gr1 (clone RB6-8C5), SIGLEC-F (clone E50-2440),
CD3 (clone 500A2), CD4 (clone RM4-5), and IL-17 (clone TC11-18H10) were purchased from BD
Biosciences. Ag85B tetramers were obtained from NIH tetramer core. For flow cytometric analysis, lung
single cell suspensions were stained with tetramer prior to surface and intracellular staining for 1 h at
37°C. Intracellular cytokine staining was performed using a BD Cytofix/Cytoperm kit (BD Biosciences)
according to the manufacturer’s instructions. Intracellular staining with anti-IFN-g and IL-17 was per-
formed for 30 min. Cells single stained with each fluorochrome were used as controls for the compensa-
tion matrix in the flow cytometry. Samples were acquired on a 4 Laser BD Fortessa flow cytometer, and
the analysis was performed using FlowJo (TreeStar).
Immunofluorescence staining. For immunofluorescent staining, formalin-fixed and paraffin-em-
bedded (FFPE) lung sections were cut, immersed in xylene, and then hydrated in 96% alcohol and PBS.
Antigens were unmasked using DakoCytomation target retrieval solution (Dako), and nonspecific bind-
ing was blocked by adding 5% (vol/vol) normal donkey serum and Fc block (BD). Avidin was used to
neutralize endogenous biotin, followed by incubation with biotin (Sigma-Aldrich). Sections were then
probed with anti-B220 (clone RA3-6B2; BD) and anti-CD3 (clone M-20; Santa Cruz Biotechnology) to
detect B and T cells, respectively. For analysis of B cell follicles, follicles were outlined with an automated
Epithelial Signaling Mediates VaccineMtb Control ®















































tool of the Zeiss Axioplan 2 microscope (Zeiss), and total area and average size was calculated in squared
microns.
Cytokine and chemokine quantification using Luminex or ELISA. Cytokine and chemokine pro-
tein contents in lung homogenates were quantified using Luminex multianalyte technology (Millipore)
according to the manufacturer’s protocols. IL-17 and IFN-g were quantified by enzyme-linked immuno-
sorbent assay (ELISA) according to the manufacturer’s instructions (R&D).
Statistical analysis. The differences between two groups were analyzed using two-tailed Student t
test in Prism 5 (GraphPad). Differences between the means of three or more groups were analyzed using
one-way analysis of variance (ANOVA) with Tukey’s post-test. For comparisons between two or more
groups with two independent variables, two-way ANOVA with Sidak’s or Tukey’s post-test was used. A P
value of ,0.05 was considered significant. Raw read counts were used as input for DESeq2 (63) (version
1.24.0) differential expression analysis, using default settings and an FDR-adjusted P value threshold of
1025 for significant differential expression. Lists of significantly differentially expressed genes were used
to test for significant enrichment among KEGG pathways (58) using WebGestalt (59) (default settings,
adjusted P= 0.05 threshold for enrichment).
Data availability. scRNA-Seq data that support the findings of this study have been deposited in
GEO (GSE150657) and synapse (syn22036882). RNA-Seq data that support the findings of this study have
been deposited in GEO (accession number GSE165614). Other data that support the findings of this
study are available from the corresponding author upon request.
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